#drug pricing

Insurance companies can no longer implement harmful co-pay accumulator policies.

In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.

Stop me if you’ve heard this one before.

A look at the 2019 State of the Union address

Louisiana health officials are adopting the country’s first subscription model for hep C cures.

Older drugs, many on the market for years, are rising in cost much faster than inflation.

A new study examines the clinical and economic impact of new direct-acting antivirals.

New recommendations in the Annals of Internal Medicine would increase access to treatment.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

New recommendations in the Annals of Internal Medicine would increase access to treatment.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

He’ll oversee the FDA, Medicare and Medicaid at a time when soaring drug prices remain a contentious political topic.

U.S. lawmakers say appointing Azar is like putting “the pharmaceutical fox in charge of the health care henhouse.”

The state’s health secretary considers a radical plan to get the U.S. government to step in and override HCV patent protections.

Nearly a quarter of Americans say they have trouble paying for medications.

The Trump administration calls for fewer of the drug coverage reviews that ensure that health plans don’t discriminate.